These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29799846)

  • 1. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
    Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
    PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
    Dail M; Wong J; Lawrence J; O'Connor D; Nakitandwe J; Chen SC; Xu J; Lee LB; Akagi K; Li Q; Aster JC; Pear WS; Downing JR; Sampath D; Shannon K
    Nature; 2014 Sep; 513(7519):512-6. PubMed ID: 25043004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
    Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
    Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
    J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
    PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines.
    Ksionda O; Melton AA; Bache J; Tenhagen M; Bakker J; Harvey R; Winter SS; Rubio I; Roose JP
    Oncogene; 2016 Jul; 35(28):3658-68. PubMed ID: 26549032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
    Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
    Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
    Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
    Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways.
    Yang T; Yao S; Zhang X; Guo Y
    Drug Des Devel Ther; 2016; 10():1389-97. PubMed ID: 27114702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.
    Soler A; Figueiredo AM; Castel P; Martin L; Monelli E; Angulo-Urarte A; Milà-Guasch M; Viñals F; Baselga J; Casanovas O; Graupera M
    Clin Cancer Res; 2016 Dec; 22(23):5805-5817. PubMed ID: 27225693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase C delta is required for survival of cells expressing activated p21RAS.
    Xia S; Forman LW; Faller DV
    J Biol Chem; 2007 May; 282(18):13199-210. PubMed ID: 17350960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
    Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.